At the moment, glucose-lowering medications generally target insulin or glucagon secretion (sulphonylureas, incretin-based therapies), insulin deficiency (replacement with exogenous insulin), insulin resistance (metformin, pioglitazone), or increased glucose elimination via urine (sodium-dependent glucose transporter-2 inhibitors)3. This evidence concerns the gene GCG and Insulin resistance.